Corvus Pharmaceuticals Inc (CRVS)
2.275
+0.08
(+3.88%)
USD |
NASDAQ |
May 20, 14:33
Corvus Pharmaceuticals Research and Development Expense (Quarterly): 4.075M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 4.075M |
December 31, 2023 | 3.999M |
September 30, 2023 | 3.965M |
June 30, 2023 | 3.968M |
March 31, 2023 | 4.594M |
December 31, 2022 | 4.08M |
September 30, 2022 | 10.36M |
June 30, 2022 | 4.923M |
March 31, 2022 | 5.10M |
December 31, 2021 | 4.788M |
September 30, 2021 | 6.991M |
June 30, 2021 | 9.106M |
March 31, 2021 | 8.23M |
December 31, 2020 | 7.191M |
September 30, 2020 | 6.619M |
June 30, 2020 | 7.857M |
March 31, 2020 | 10.16M |
December 31, 2019 | 8.92M |
September 30, 2019 | 8.996M |
Date | Value |
---|---|
June 30, 2019 | 10.64M |
March 31, 2019 | 9.419M |
December 31, 2018 | 8.394M |
September 30, 2018 | 8.374M |
June 30, 2018 | 9.715M |
March 31, 2018 | 12.10M |
December 31, 2017 | 9.688M |
September 30, 2017 | 10.73M |
June 30, 2017 | 12.39M |
March 31, 2017 | 13.50M |
December 31, 2016 | 9.132M |
September 30, 2016 | 7.707M |
June 30, 2016 | 7.119M |
March 31, 2016 | 5.397M |
December 31, 2015 | 4.909M |
September 30, 2015 | 2.514M |
June 30, 2015 | 2.005M |
March 31, 2015 | 1.924M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.965M
Minimum
Sep 2023
10.64M
Maximum
Jun 2019
6.728M
Average
6.805M
Median
Research and Development Expense (Quarterly) Benchmarks
Cyclacel Pharmaceuticals Inc | 3.518M |
Enanta Pharmaceuticals Inc | 35.58M |
Oragenics Inc | 11.04M |
Nanoviricides Inc | 1.215M |
MAIA Biotechnology Inc | 2.321M |